Ireland· IE-PA-EU/1/24/1881/001-002
Alhemo 15 mg/1.5 mL solution for injection in pre-filled pen
A concizumab product containing concizumab, registered in Ireland by Novo Nordisk A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Concizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BX10 (concizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Concizumab · ATC B02BX10
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of concizumab costs, country by country.
Normalised to the WHO defined daily dose (14 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Concizumab · price per daily dose (14 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1227.21
The record
At a glance
HPRA (Ireland)- Active substance
- Concizumab
- Manufacturer
- Novo Nordisk A/S
- Country
- Ireland (IE)
- ATC code
- B02BX10
- ATC class
- Concizumab
- Defined daily dose
- 14 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1881/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Concizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAlhemo 15 mg/1,5 ml oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
- CzechiaALHEMONovo Nordisk A/S, Bagsvaerd
- PolandAlhemoNovo Nordisk A/S
- SwedenAlhemo 15 mg/1,5 ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- FinlandAlhemoNovo Nordisk A/S
- BelgiumAlhemo 15 mg/1.5 mlNovo Nordisk
- SwitzerlandAlhemo
- IcelandAlhemoNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Alhemo
- Norway · Alhemo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f23ea338-56ea-44d1-beee-65e90dca3dac GET /v1/drugs/f23ea338-56ea-44d1-beee-65e90dca3dac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"B02BX10"
],
"strength": null,
"pa_number": "EU/1/24/1881/001-002",
"substances": [
"Concizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "13/12/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about concizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.